Substance use disorder and the early course of illness in schizophrenia and affective psychosis

Schizophrenia Bulletin
B KovasznayE J Bromet

Abstract

The relationship between a history of substance use disorder and the early course of psychotic illness was examined in 96 subjects with schizophrenia and 106 subjects with affective psychosis followed in the Suffolk County Mental Health Project, a longitudinal study of first-admission psychosis. Subjects received a structured diagnostic interview and clinical ratings at baseline assessment and again 6 months later. The 6-month assessment included information about treatment received during the interval. A lifetime history of substance use disorder was associated with worse clinical functioning at 6 months for schizophrenia subjects, but not for those with affective psychosis. There were no significant associations of substance use disorder with type of treatment during the interval or with self-reported compliance with medication. Schizophrenia subjects were more likely than subjects with affective psychosis to report cannabis use during the interval and to meet criteria for cannabis use disorder.

Citations

Nov 30, 2006·European Archives of Psychiatry and Clinical Neuroscience·Thomas WobrockDieter Caspari
Feb 6, 2009·European Archives of Psychiatry and Clinical Neuroscience·Thomas WobrockPeter Falkai
Aug 22, 2012·European Archives of Psychiatry and Clinical Neuroscience·Berend MalchowThomas Wobrock
Oct 3, 2013·European Archives of Psychiatry and Clinical Neuroscience·Berend MalchowThomas Wobrock
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Katerina ZavitsanouXu Feng Huang
Dec 7, 2000·Chemistry and Physics of Lipids·A Giuffrida, D Piomelli
Apr 29, 2000·Prostaglandins & Other Lipid Mediators·A GiuffridaD Piomelli
Mar 18, 2000·Clinical Psychology Review·J J BlanchardA R Sherwood
Jun 1, 2001·Progress in Neuro-psychopharmacology & Biological Psychiatry·M Glass
Jan 5, 2002·Journal of Substance Abuse Treatment·K H LittrellC G Johnson
Jul 6, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·P Batel
Sep 17, 2004·Journal of Psychoactive Drugs·Icro MaremmaniGiulio Perugi
Jul 29, 2006·Schizophrenia Bulletin·Carol L M CatonBella Schanzer
Jan 22, 2000·BMJ : British Medical Journal·J StrangW Hall
Sep 3, 2011·Psychiatric Services : a Journal of the American Psychiatric Association·Jennifer P WisdomRobert E Drake
Sep 1, 2012·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Krzysztof KrystaJanusz K Rybakowski
Mar 6, 2003·CNS Drugs·J Ludovic Croxford
Dec 21, 2013·Psychiatry Research·Angelo CocchiUNKNOWN Desio Early Intervention Service Team
Oct 4, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Bob GreenDavid Kavanagh
Jul 24, 2014·Journal of Addiction Medicine·Carla GramagliaPatrizia Zeppegno
Oct 31, 2002·The Australian and New Zealand Journal of Psychiatry·Lisa J PhillipsPatrick D McGorry
Nov 7, 1998·The Australian and New Zealand Journal of Psychiatry·N Siegfried
Dec 5, 2015·Expert Opinion on Pharmacotherapy·Jean-Michel AzorinRaoul Belzeaux
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Mar 31, 2015·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Mar 28, 2009·European Psychiatry : the Journal of the Association of European Psychiatrists·Gisela SugranyesMiquel Bernardo
Oct 14, 2008·Annales pharmaceutiques françaises·J Costentin
Dec 9, 2008·Comprehensive Psychiatry·Cheng-Fang YenCheng-Sheng Chen
Apr 9, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·T Wobrock, M Soyka
Jan 24, 2007·Clinical Psychology Review·Lynsey GreggGillian Haddock
Nov 18, 2003·Acta Psychiatrica Scandinavica·S H MutsatsaT R E Barnes
May 17, 2008·Addiction Biology·F Markus Leweke, Dagmar Koethe
Nov 15, 2013·Early Intervention in Psychiatry·Jean AddingtonKristin S Cadenhead
Feb 12, 2008·The American Journal of Medicine·Alan N Elias, Heather Hofflich
Nov 30, 2005·Schizophrenia Research·Alain DervauxMarie-Odile Krebs
Jul 16, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Anton GrechRobin M Murray

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Biological Psychiatry
M Hambrecht, H Häfner
European Archives of Psychiatry and Clinical Neuroscience
M SoykaP Sand
Fortschritte der Neurologie-Psychiatrie
T WobrockF-G Pajonk
The British Journal of Psychiatry : the Journal of Mental Science
R CantwellG Harrison
© 2021 Meta ULC. All rights reserved